Privium Fund Management B.V. Invests $222,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Privium Fund Management B.V. acquired a new position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 77,500 shares of the company’s stock, valued at approximately $222,000. Privium Fund Management B.V. owned approximately 0.08% of Poseida Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in PSTX. Marshall Wace LLP purchased a new stake in shares of Poseida Therapeutics in the 2nd quarter valued at about $31,000. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics in the first quarter valued at approximately $33,000. Rothschild Investment LLC bought a new stake in Poseida Therapeutics during the second quarter valued at approximately $35,000. Principal Financial Group Inc. purchased a new position in Poseida Therapeutics in the 2nd quarter worth approximately $35,000. Finally, Mackenzie Financial Corp purchased a new position in Poseida Therapeutics in the 2nd quarter worth approximately $51,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Price Performance

PSTX opened at $3.08 on Friday. The stock has a market capitalization of $299.16 million, a P/E ratio of -2.59 and a beta of 0.54. The company has a current ratio of 2.48, a quick ratio of 2.48 and a debt-to-equity ratio of 0.97. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $4.27. The stock has a 50-day moving average price of $2.76 and a 200-day moving average price of $2.87.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a research report on Friday.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.